Disulfide conjugation chemistry: a mixed blessing for therapeutic drug delivery?

Maarten Danial, Almar Postma
  • Therapeutic Delivery, June 2017, Future Science
  • DOI: 10.4155/tde-2017-0003

Editorial piece discussing the issues around disulfide conjugation strategies.

What is it about?

Therapeutics against cancer and viral infections commonly suffer from several drawbacks including non-selective cytotoxicity, high immunogenicity and low circulation half-lives. The last decade has shown that these therapeutics have embraced conjugation of synthetic polymers and antibodies to therapeutic and cytotoxic payloads. Thiol-thiol coupling (disulfide conjugation) has been a tremendously popular conjugation strategy, in part due to its orthogonality, is amenable to biological and non-biological therapeutics and allows for modulating the strength of the conjugation through groups adjacent to the disulfide.

Why is it important?

The ease of disulphide-conjugation have been overshadowed by mixed results obtained from in vitro and in vivo experiments. This piece highlights the failures and successes of disulfide chemistry in light of these mixed results.

Perspectives

Dr Almar Postma (Author)
CSIRO

This was a 2nd invite to write an editorial for Therapeutic Delivery and an opportunity for my colleague to condense his thoughts and opinions about an area of work he was actively working in.

The following have contributed to this page: Dr Almar Postma

In partnership with: